Associations between acute GVHD-related biomarkers and endothelial cell activation after allogeneic hematopoietic stem cell transplantation.

[1]  T. Kyo,et al.  Relationship between HMGB1 and PAI-1 after allogeneic hematopoietic stem cell transplantation , 2016, Journal of blood medicine.

[2]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[3]  T. Ikezoe.  Thrombomodulin/activated protein C system in septic disseminated intravascular coagulation , 2015, Journal of Intensive Care.

[4]  T. Kyo,et al.  Recombinant Thrombomodulin for the Treatment of Transplantation-Associated Coagulopathy after Allogeneic Hematopoietic Stem Cell Transplantation , 2014 .

[5]  T. Kyo,et al.  The Preventative Effects of Recombinant Thrombomodulin on Transplantation-Associated Coagulopathy after Allogeneic Hematopoietic Stem Cell Transplantation , 2014 .

[6]  T. Luft,et al.  High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus-host disease in the absence of statin therapy , 2014, Haematologica.

[7]  Y. Maeda.  Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses , 2013, International Journal of Hematology.

[8]  T. Braun,et al.  ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. , 2013, The New England journal of medicine.

[9]  Yi-Bin Chen,et al.  Biomarkers for acute GVHD: can we predict the unpredictable? , 2013, Bone Marrow Transplantation.

[10]  J. Bolaños-Meade,et al.  Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study. , 2012, Blood.

[11]  T. Silva,et al.  Platelet‐activating factor receptor plays a role in the pathogenesis of graft‐versus‐host disease by regulating leukocyte recruitment, tissue injury, and lethality , 2012, Journal of leukocyte biology.

[12]  T. Luft,et al.  Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. , 2011, Blood.

[13]  I. Miura,et al.  Successful treatment of refractory acute GVHD complicated by severe intestinal transplant-associated thrombotic microangiopathy using recombinant thrombomodulin. , 2011, Thrombosis research.

[14]  T. Nakanishi,et al.  Can recombinant thrombomodulin play a preventive role for veno-occlusive disease after haematopoietic stem cell transplantation? , 2011, Thrombosis and Haemostasis.

[15]  C. Dinarello,et al.  Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. , 2011, Blood.

[16]  H. Stroissnig,et al.  Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue , 2010, Thrombosis and Haemostasis.

[17]  N. Komatsu,et al.  Successful treatment of sinusoidal obstructive syndrome after hematopoietic stem cell transplantation with recombinant human soluble thrombomodulin , 2010, Bone Marrow Transplantation.

[18]  T. Ikezoe,et al.  Successful treatment of transplantation-associated thrombotic microangiopathy with recombinant human soluble thrombomodulin , 2010, Bone Marrow Transplantation.

[19]  A. Gratwohl,et al.  Leukocyte count and risk of thrombosis in patients undergoing haematopoietic stem cell transplantation or intensive chemotherapy , 2010, Thrombosis and Haemostasis.

[20]  R. Jenq,et al.  Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer , 2010, Nature Reviews Cancer.

[21]  H. Sengeløv,et al.  Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[22]  J. Ritz,et al.  Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  B. Storer,et al.  Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. , 2009, Blood.

[24]  S. Nomura,et al.  The significance of EMAP-II after allogeneic stem cell transplantation. , 2009, Transplant immunology.

[25]  Thomas M Braun,et al.  A biomarker panel for acute graft-versus-host disease. , 2009, Blood.

[26]  T. Braun,et al.  Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. , 2008, Blood.

[27]  A. Gratwohl,et al.  Vascular endothelium as 'novel' target of graft-versus-host disease. , 2008, Best practice & research. Clinical haematology.

[28]  H. Kitayama,et al.  Role of soluble tumor necrosis factor-related apoptosis-inducing ligand concentrations after stem cell transplantation. , 2007, Transplant immunology.

[29]  Richard T. Lee,et al.  IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. , 2007, The Journal of clinical investigation.

[30]  W. Shlomchik.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[31]  N. Aoki,et al.  Efficacy and safety of recombinant human soluble thrombomodulin (ART‐123) in disseminated intravascular coagulation: results of a phase III, randomized, double‐blind clinical trial , 2007, Journal of thrombosis and haemostasis : JTH.

[32]  H. Kitayama,et al.  Role of platelet-derived chemokines (RANTES and ENA-78) after stem cell transplantation. , 2006, Transplant immunology.

[33]  A. Will,et al.  Diagnosis of acute graft-versus-host disease. , 2006, Transplantation.

[34]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[35]  R. Soiffer,et al.  Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[36]  Avital Lev,et al.  Vascular Endothelial Cells Have Impaired Capacity to Present Immunodominant, Antigenic Peptides: A Mechanism of Cell Type-Specific Immune Escape1 , 2005, The Journal of Immunology.

[37]  Y. Kodera,et al.  Intestinal thrombotic microangiopathy after allogeneic bone marrow transplantation: a clinical imitator of acute enteric graft-versus-host disease , 2004, Bone Marrow Transplantation.

[38]  A. Ganser,et al.  Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[39]  M. V. D. van den Brink,et al.  Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. , 2001, Blood.

[40]  S. Imashuku,et al.  Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. , 1997, International journal of hematology.

[41]  A. Rowbottom,et al.  Monitoring cytokine production in peripheral blood during acute graft-versus-host disease following allogeneic bone marrow transplantation. , 1993, Bone marrow transplantation.

[42]  G. McDonald,et al.  Veno-occlusive Disease of the Liver and Multiorgan Failure after Bone Marrow Transplantation: A Cohort Study of 355 Patients , 1993, Annals of Internal Medicine.

[43]  S. Yamamoto,et al.  A domain composed of epidermal growth factor-like structures of human thrombomodulin is essential for thrombin binding and for protein C activation. , 1989, The Journal of biological chemistry.

[44]  L. Grochow,et al.  VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION , 1987, Transplantation.

[45]  T. Ikezoe,et al.  Thrombomodulin alleviates murine GVHD in association with an increase in the proportion of regulatory T cells in the spleen , 2015, Bone Marrow Transplantation.

[46]  J. Goldberg,et al.  High day 28 ST2 levels predict for acute graft-versus-host disease and transplant-related mortality after cord blood transplantation. , 2015, Blood.

[47]  T. Luft,et al.  Endothelial vulnerability and endothelial damage are associated with risk of graft-versus-host disease and response to steroid treatment. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[48]  A. Castiglioni,et al.  High-mobility group box 1 (HMGB1) as a master regulator of innate immunity , 2010, Cell and Tissue Research.